Publications by authors named "Jan Liptrot"
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects.
View Article and Find Full Text PDFIntroduction: HTL0018318 is a selective muscarinic M receptor partial agonist under development for the symptomatic treatment of dementias, including Alzheimer's disease. Clinically, HTL0018318 would likely be used alone or in conjunction with cholinesterase inhibitors (e.g.
View Article and Find Full Text PDFArticle Synopsis
- HTL0009936 is being tested as a treatment for cognitive dysfunction in Alzheimer's disease, focusing on its safety, tolerability, and pharmacokinetics in elderly patients with below average cognitive functioning.
- The study involved two parts: one evaluated HTL0009936's effects on healthy elderly subjects, while the second part used a randomized approach to assess its effects in subjects with cognitive impairments, measuring cognitive and electrical brain responses.
- Results indicate that HTL0009936 is generally safe and well-tolerated, showing some effects on brain activity (P300), but no conclusive evidence of significant cognitive improvement due to design changes that limited optimal drug exposure during testing.
Background: The cholinergic system and M receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia's including Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). We investigated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple doses of HTL0018318 in healthy younger adults and elderly subjects.
View Article and Find Full Text PDFAims: HTL0018318 is a selective M receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety, tolerability, pharmacokinetics and exploratory pharmacodynamics (PD) of HTL0018318 following single ascending doses.
Methods: This randomized, double-blind, placebo-controlled study in 40 healthy younger adult and 57 healthy elderly subjects, investigated oral doses of 1-35 mg HTL0018318.